

IFW



ATTORNEY DOCKET NO. 04137.0003U3
APPLICATION NO. 10/652,622

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	
)	
NI <i>et al.</i>)	Confirmation No: 1025
)	
Serial No.: 10/652,622)	Group Art: 1635
)	
Filed: August 29, 2003)	Examiner: Unassigned
)	
For: "DELIVERY OF PHYSIOLOGICAL AGENTS)	
WITH <i>IN-SITU</i> GELS COMPRISING ANIONIC)	
POLYSACCHARIDES")	

STATUS INQUIRY IN VIEW OF MISSING PARTS

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

NEEDLE & ROSENBERG, P.C.
Customer Number 23859

June 10, 2004

Sirs:

The captioned application was filed without inclusion of payment of fees or inventor's Oaths/Declarations on August 29, 2003, and Applicants have received their date-stamped return receipt postcard (copy attached) showing the serial number of the application and receipt of the application and associated filing papers. Applicants have not however received the expected Notice of Missing Parts, and it therefore appears the processing of the application by the Commissioner may be experiencing problems. Applicants respectfully request that the Office inquire into the status of this application and address any processing problems, so that a Notice of

ATTORNEY DOCKET NO. 04137.0003U3
APPLICATION NO. 10/652,622


Missing Parts is issued, and publication of the application can proceed.

An Information Disclosure Statement, Form PTO-1449, and copies of needed references are also attached herewith.

When a proper Notice of Missing Parts or other document clarifying the status of the processing of the application is received, Applicants will soon thereafter submit appropriate payments for the application filing fees, and any other required fees.

Respectfully submitted,

NEEDLE & ROSENBERG, P.C.




Mark A. Murphy, Ph.D.
Registration No. 42,915


NEEDLE & ROSENBERG, P.C.
Customer Number 23859
(678) 420-9300 Phone
(678) 420-9301 Fax

CERTIFICATE OF MAILING

I hereby certify that this correspondence, including any items indicated as attached or included, is being deposited with the United States Postal Service in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date indicated below.



Mark A. Murphy, Ph.D.



Date



ATTORNEY DOCKET NO. 04137.0003U3
APPLICATION NO. 10/652,622

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	
)	
NI <i>et al.</i>)	Confirmation No: 1025
)	
Serial No.: 10/652,622)	Group Art: 1635
)	
Filed: August 29, 2003)	Examiner: Unassigned
)	
For: "DELIVERY OF PHYSIOLOGICAL AGENTS)	
WITH <i>IN-SITU</i> GELS COMPRISING ANIONIC)	
POLYSACCHARIDES")	

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

NEEDLE & ROSENBERG, P.C.
Customer Number 23859

June 10, 2004

Sir:

Pursuant to the requirements of 37 C.F.R. § 1.56, submitted herewith on the accompanying Form PTO 1449 is a listing of documents known to Applicants and/or their attorneys. Some of the documents cited were cited by or submitted to the Patent Office in Application No. 09/795,987, filed February 28, 2001, to which the present application claims priority. These documents are indicated by a double asterisk (**) on the Form PTO 1449. Pursuant to 37 C.F.R. § 1.98(d), copies of these documents are not enclosed. A copy of each of the remaining documents is enclosed.

ATTORNEY DOCKET NO. 04137.0003U3
APPLICATION NO. 10/652,622

In accordance with the provisions of M.P.E.P. § 2001.06(b) and 37 C.F.R. § 1.98(b)(3), Applicants would like to bring to the attention of the Examiner the existence of the co-pending patent application(s) identified below, which were filed in the United States Patent and Trademark Office:

	<u>Application No.</u>	<u>Date Filed</u>	<u>Inventors</u>	<u>Attorney Docket No.</u>
1.	09/795,897	02/28/2001	Ni <i>et al.</i>	04137.0003U1
2.	09/325,610	06/03/1999	Ni <i>et al.</i>	04137.0002U2
3.	10/422,867	04/23/2003	Ni <i>et al.</i>	04137.0002U3
4.	60/573,790	05/24/2004	Ni <i>et al.</i>	04137.0004U1

In accordance with the requirements of 37 C.F.R. § 1.98(a)(2)(iii), a copy of the above-referenced application specification(s), including the claims and drawings thereof, is enclosed.


Consideration of the cited documents and making the same of record in the prosecution of the above-referenced application are respectfully requested.

ATTORNEY DOCKET NO. 04137.0003U3
APPLICATION NO. 10/652,622

No fee is believed due; however, the Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to Deposit Account No. 14-0629.

Respectfully submitted,


NEEDLE & ROSENBERG, P.C.



Mark A. Murphy, Ph.D.
Registration No. 42,915

NEEDLE & ROSENBERG, P.C.
Customer Number 23859
(678) 420-9300 Phone
(678) 420-9301 Fax

CERTIFICATE OF MAILING

I hereby certify that this correspondence, including any items indicated as attached or included, is being deposited with the United States Postal Service in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date indicated below.


Mark A. Murphy, Ph.D.


Date



Substitute for Form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 9

Complete if Known

Application Number	10/652,622
Filing Date	August 29, 2003
First Name Inventor	NI <i>et al.</i>
Art Unit	1635
Examiner Name	Unassigned
Attorney Docket Number	04137.0003U3

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document No.		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)				
	A1	**	US-3,982,003	09/21/1976	Mitchell <i>et al.</i>	
	A2	**	US-4,199,560	04/22/1980	Gyarmati <i>et al.</i>	
	A3	**	US-4,305,933	12/15/1981	Wiczer	
	A4	**	US-4,500,510	02/19/1985	Goldstein	
	A5	**	US-4,613,500	09/23/1986	Suzuki <i>et al.</i>	
	A6	**	US-4,652,441	03/24/1987	Okada et al.	
	A7	**	US-4,711,782	12/08/1987	Okada et al.	
	A8	**	US-4,725,438	02/16/1988	Leazer	
	A9	**	US-4,847,091	07/11/1989	Illum	
	A10	**	US-4,842,866	06/27/1989	Horder <i>et al.</i>	
	A11	**	US-4,917,890	04/17/1990	McAnalley	
	A12	**	US-4,917,893	04/17/1990	Okada et al.	
	A13	**	US-4,925,677	05/15/1990	Feijen	
	A14	**	US-4,981,875	01/01/1991	Leusner <i>et al.</i>	
	A15	**	US-5,059,189	10/22/1991	Cilento <i>et al.</i>	
	A16	**	US-5,061,492	10/29/1991	Okada <i>et al.</i>	
	A17	**	US-5,064,650	11/12/1991	Lew	
	A18	**	US-5,071,644	12/10/1991	Viegas <i>et al.</i>	
	A19	**	US-5,079,018	01/07/1992	Ecanow	
	A20	**	US-5,147,648	09/15/1992	Bannert	
	A21	**	US-5,188,825	02/23/1993	Iles <i>et al.</i>	
	A22	**	US-5,192,802	03/09/1993	Rencher	
	A23	**	US-5,204,108	04/20/1993	Illum	
	A24	**	US-5,208,031	05/04/1993	Kelly	
	A25	**	US-5,238,917	08/24/1993	Fujii <i>et al.</i>	
	A26	**	US-5,266,318	11/30/1993	Taylor-McCord	
	A27	**	US-5,284,659	02/08/1994	Cherukuri et al	
	A28	**	US-5,288,498	02/22/1994	Stanley <i>et al.</i>	
	A29	**	US-5,288,500	02/22/1994	Ibsen	
	A30	**	US-5,314,915	05/24/1994	Rencher	
	A31	**	US-5,318,780	06/07/1994	Viegas <i>et al.</i>	
	A32	**	US-5,362,424	11/08/1994	Lee et al.	

**Documents indicated with ** have been previously submitted in a parent application.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant to place a check mark here if English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 9

Complete if Known

Application Number	10/652,622
Filing Date	August 29, 2003
First Name Inventor	NI <i>et al.</i>
Art Unit	1635
Examiner Name	Unassigned
Attorney Docket Number	04137.0003U3

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document No.		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)				
	A33	**	US-5,409,703	04/25/1995	McAnalley <i>et al.</i>	
	A34	**	US-5,435,997	07/25/1995	Burns	
	A35	**	US-5,503,822	04/02/1996	Schulman	
	A36	**	US-5,505,966	04/09/1996	Edman <i>et al.</i>	
	A37	**	US-5,508,043	04/16/1996	Krishnamurthy	
	A38	**	US-5,512,306	04/30/1996	Carlsson <i>et al.</i>	
	A39	**	US-5,525,634	06/11/1996	Sintov <i>et al.</i>	
	A40	**	US-5,545,673	08/13/1996	Kelly	
	A41	**	US-5,571,531	11/05/1996	McDermott <i>et al.</i>	
	A42	**	US-5,578,307	11/26/1996	Wunderlich <i>et al.</i>	
	A43	**	US-5,587,175	12/24/1996	Viegas <i>et al.</i>	
	A44	**	US-5,599,551	02/04/1997	Kelly	
	A45	**	US-5,612,053	04/14/1998	Baichwal <i>et al.</i>	
	A46	**	US-5,622,717	04/22/1997	Fuisz	
	A47	**	US-5,639,795	06/17/1997	Friedman <i>et al.</i>	
	A48	**	US-5,645,827	07/08/1997	Marlin <i>et al.</i>	
	A49	**	US-5,648,399	07/15/1997	Friedman <i>et al.</i>	
	A50	**	US-5,651,987	07/29/1997	Fuisz	
	A51	**	US-5,674,495	10/07/1997	Bowersock <i>et al.</i>	
	A52	**	US-5,707,644	01/13/1998	Illum	
	A53	**	US-5,738,865	04/14/1998	Baichwal <i>et al.</i>	
	A54	**	US-5,760,102	06/02/1998	Hall <i>et al.</i>	
	A55	**	US-5,770,582	06/23/1998	von Borstel <i>et al.</i>	
	A56	**	US-5,804,212	09/08/1998	Illum	
	A57	**	US-5,811,123	09/22/1998	Fuisz	
	A58	**	US-5,840,332	11/24/1998	Lerner <i>et al.</i>	
	A59	**	US-5,849,327	12/15/1998	Berliner <i>et al.</i>	
	A60	**	US-5,866,619	02/02/1999	Sintov <i>et al.</i>	
	A61	**	US-5,900,238	05/04/1999	Gombotz <i>et al.</i>	
	A62	**	US-5,902,796	05/11/1999	Shand <i>et al.</i>	
	A63	**	US-5,929,051	07/27/1999	Ni <i>et al.</i>	
	A64	**	US-5,935,604	08/10/1999	Illum	

**Documents indicated with ** have been previously submitted in a parent application.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

3

of

9

Complete if Known

Application Number	10/652,622
Filing Date	August 29, 2003
First Name Inventor	NI <i>et al.</i>
Art Unit	1635
Examiner Name	Unassigned
Attorney Docket Number	04137.0003U3

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document No.		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)				
	A65	**	US-5,942,242	08/24/1999	Mizushima <i>et al.</i>	
	A66	**	US-5,948,749	09/07/1999	Igarashi <i>et al.</i>	
	A67	**	US-5,958,443	09/28/1999	Viegas <i>et al.</i>	
	A68	**	US-6,033,651	03/07/2000	Dolak <i>et al.</i>	
	A69	**	US-6,060,078	05/09/2000	Lee	
	A70	**	US-6,063,915	05/16/2000	Hansen <i>et al.</i>	
	A71	**	US-6,083,531	07/04/2000	Humbert-Droz <i>et al.</i>	
	A72	**	US-6,083,540	07/04/2000	Christensen <i>et al.</i>	
	A73	**	US-6,103,269	08/15/2000	Wunderlich <i>et al.</i>	
	A74	**	US-6,133,440	10/17/2000	Qiu <i>et al.</i>	
	A75	**	US-6,136,334	10/24/2000	Viegas <i>et al.</i>	
	A76	**	US-6,139,880	10/31/2000	Dolak <i>et al.</i>	
	A77	**	US-6,149,940	11/21/2000	Maggi <i>et al.</i>	
	A78	**	US-6,159,491	12/12/2000	Durrani	
	A79	**	US-6,171,594	01/09/2001	Nielsen	
	A80	**	US-6,174,549	01/16/2001	Greenshields <i>et al.</i>	
	A81	**	US-6,197,327	03/06/2001	Harrison <i>et al.</i>	
	A82	**	US-6,197,346	03/06/2001	Mathiowitz <i>et al.</i>	
	A83	**	US-6,210,710	04/03/2001	Skinner	
	A84	**	US-6,217,908	04/17/2001	Mathiowitz <i>et al.</i>	
	A85	**	US-6,228,387	05/08/2001	Borod	
	A86	**	US-6,228,396	05/08/2001	Watts	
	A87	**	US-6,231,888	05/15/2001	Lerner <i>et al.</i>	
	A88	**	US-6,248,360	06/19/2001	Choi <i>et al.</i>	
	A89	**	US-6,261,574	07/17/2001	Costello	
	A90	**	US-6,274,548	08/14/2001	Ni <i>et al.</i>	
	A91	**	US-6,284,273	09/04/2001	Lenaerts <i>et al.</i>	
	A92	**	US-6,290,964	09/18/2001	Shupe <i>et al.</i>	
	A93	**	US-6,309,675	10/30/2001	Sobczak	
	A94	**	US-6,310,089	10/30/2001	Watts et al.	
	A95	**	US-6,313,103	11/06/2001	Ni <i>et al.</i>	
	A96	**	US-6,333,194	12/25/2001	Levy et al.	

**Documents indicated with ** have been previously submitted in a parent application.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

4

of

9

Complete if Known

Application Number	10/652,622
Filing Date	August 29, 2003
First Name Inventor	NI <i>et al.</i>
Art Unit	1635
Examiner Name	Unassigned
Attorney Docket Number	04137.0003U3

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document No.		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)				
	A97	**	US-6,342,251	01/29/2000	Illum <i>et al.</i>	
	A98	**	US-6,350,469	02/26/2002	Daggy <i>et al.</i>	
	A99	**	US-6,355,276	03/12/2002	Illum <i>et al.</i>	
	A100	**	US-6,358,525	03/19/2002	Guo <i>et al.</i>	
	A101	**	US-6,365,200	04/02/2002	Birnholtz <i>et al.</i>	
	A102	**	US-6,365,624	04/02/2002	Davidson <i>et al.</i>	
	A103	**	US-6,368,639	04/09/2002	Farooqui <i>et al.</i>	
	A104	**	US-6,375,963	04/23/2002	Repka <i>et al.</i>	
	A105	**	US-6,375,988	04/23/2002	Suzuki <i>et al.</i>	
	A106	**	US-6,383,495	05/07/2002	Ramakrishna <i>et al.</i>	
	A107	**	US-6,383,513	05/07/2002	Watts <i>et al.</i>	
	A108	**	US-6,387,394	05/14/2002	Baichwal <i>et al.</i>	
	A109	**	US-6,387,408	05/14/2002	Illum <i>et al.</i>	
	A110	**	US-6,387,917	05/14/2002	Illum <i>et al.</i>	
	A111	**	US-6,391,318	05/21/2002	Illum <i>et al.</i>	
	A112	**	US-6,413,494	07/02/2002	Lee <i>et al.</i>	
	A113	**	US-6,413,941	07/02/2002	Garnett <i>et al.</i>	
	A114	**	US-6,416,779	07/09/2002	D'Augustine <i>et al.</i>	
	A115	**	US-6,423,345	07/23/2002	Bernstein <i>et al.</i>	
	A116	**	US-6,432,440	08/13/2002	Watts <i>et al.</i>	
	A117	**	US-6,436,461	08/20/2002	Bouwmeesters <i>et al.</i>	
	A118	**	US-6,451,351	09/17/2002	Kawashima <i>et al.</i>	
	A119	**	US-6,455,066	09/24/2002	Fischer <i>et al.</i>	
	A120	**	US-6,465,626	10/15/2002	Watts <i>et al.</i>	
	A121	**	US-6,475,526	11/05/2002	Smith	
	A122	**	US-6,517,868	02/11/2003	Fassihi <i>et al.</i>	
	A123	**	US-6,531,152	03/11/2003	Lerner <i>et al.</i>	
	A124	**	US-6,534,065	03/18/2003	Makin <i>et al.</i>	
	A125	**	US-6,541,035	04/01/2003	Pallado <i>et al.</i>	
	A126	**	US-6,551,631	04/22/2003	Shupe <i>et al.</i>	
	A127	**	US-6,552,024	04/22/2003	Chen <i>et al.</i>	
	A128	**	US-6,558,792	05/06/2003	Vaabengaard <i>et al.</i>	

**Documents indicated with ** have been previously submitted in a parent application.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Substitute for Form 1449/PTO <h2 style="text-align: center; margin: 0;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center; margin: 0;">(Use as many sheets as necessary)</p>				Complete if Known Application Number: 10/652,622 Filing Date: August 29, 2003 First Name Inventor: NI <i>et al.</i> Art Unit: 1635 Examiner Name: Unassigned Attorney Docket Number: 04137.0003U3	
Sheet	5	of	9		

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Document No.		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)				
	A129	**	US-6,562,363	05/13/2003	Mantelle <i>et al.</i>	
	A130	**	US-6,569,463	05/27/2003	Patel <i>et al.</i>	
	A131	**	US-6,596,297	07/22/2003	Neurath <i>et al.</i>	
	A132	**	US-6,582,728	06/24/2003	Platz <i>et al.</i>	
	A133	**	US2002/0176846 A1	11/28/2002	Hastedt <i>et al.</i>	
	A134	**	US2002/0086829 A1	07/04/2002	Geffer	
	A135	**	US2002/0058624 A1	05/16/2002	Hanyu <i>et al.</i>	
	A136	**	US2002/0009418 A1	01/24/2002	Steiner <i>et al.</i>	
	A137	**	US2001/0046519 A1	11/29/2001	Illum <i>et al.</i>	

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ ^(if known)					
	A138	**	WO 99/27905	06/10/1999	Illum <i>et al.</i> (PCT)		
	A139	**	WO 98/47535	10/29/1998	Watts <i>et al.</i> (PCT)		
	A140	**	RU 324263	12/23/1971	Aimukhamedova <i>et al.</i> (English translation provided)		

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.
	** A141	ALBERSHEIM <i>et al.</i> , "Splitting of Pectin Chain Molecules in Neutral Solutions," <i>Biochemistry and Biophysics</i> , 90:46-51 (1960)
	** A142	ANDERSON, "Human Gene Therapy," <i>Nature</i> , 392:25-30 (1998)
	A143	ANDERSON <i>et al.</i> , "Protection of Cattle Against Rinderpest by Intranasal Immunisation with a Dry Powder Tissue Culture Vaccine," <i>Vaccine</i> , 19:840-843 (2001)
	** A144	ASHFORD <i>et al.</i> , "Studies on Pectin Formulations for Colonic Drug Delivery," <i>Journal of Controlled Release</i> , 30:225-232 (1994)
	** A145	ASHFORD <i>et al.</i> , "An Evaluation of Pectin as a Carrier for Drug Targeting to the Colon," <i>Journal of Controlled Release</i> , 26:213-220 (1993)
	** A146	AUSTIN <i>et al.</i> , "The Effect of Calcium Pectinate Gel Implants on the Healing of Experimental Defects in the Femora of Albino Rats," <i>S. Afr. J. Med. Sci.</i> , 38:55-60 (1973)
	** A147	AXELOS <i>et al.</i> , "Influence of the Substitutents of the Carboxyl Groups and of the Rhamnose Content of the Solution Properties and Flexibility of Pectins," <i>Int. J. Biol. Macromol.</i> , 13:77-82 (1991)

**Documents indicated with ** have been previously submitted in a parent application.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 6 of 9

Complete if Known

Application Number	10/652,622
Filing Date	August 29, 2003
First Name Inventor	NI <i>et al.</i>
Art Unit	1635
Examiner Name	Unassigned
Attorney Docket Number	04137.0003U3

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.
	** A148	AYDIN <i>et al.</i> , "Preparation and Evaluation of Pectin Beads," <i>Int'l Journal of Pharmaceutics</i> , 137:133-136 (1996)
	** A149	BLUMENKRANTZ <i>et al.</i> , "New Method for Quantitative Determination of Uronic Acids," <i>Analytical Biochemistry</i> , 54:484-489 (1973)
	** A150	COHEN <i>et al.</i> , "A Novel In Situ-Forming Ophthalmic Drug Delivery System from Alginates Undergoing Gelation in the Eye," <i>Journal of Controlled Release</i> , 44:201-208 (1997)
	A151	DAVIS <i>et al.</i> , "Absorption Enhancers for Nasal Drug Delivery," <i>Clinical Pharmacokinetics</i> , 42(13):1107-1128 (2003)
	A152	DAVIS, "Nasal Vaccines," <i>Advanced Drug Delivery Reviews</i> , 51:21-42 (2001)
	A153	DYER <i>et al.</i> , "Nasal Delivery of Insulin Using Novel Chitosan Based Formulations: A Comparative Study in Two Animal Models Between Simple Chitosan Formulations and Chitosan Nanoparticles," <i>Pharmaceutical Research</i> , 19(7):998-1008 (2002)
	** A154	ECK <i>et al.</i> , "Gene-Based Therapy," <i>Goodman and Gilman's Pharmacacological Basis of Therapeutics</i> , McGraw-Hill Publishers, 5:77-101 (1995)
	** A155	ENGLAND <i>et al.</i> , "Nasal pH Measurement: A Reliable and Repeatable Parameter," <i>Clinical Otolaryngology</i> , 24:67-68 (1999)
	** A156	FISHER <i>et al.</i> , "Assessment of Accidental Intakes of Uranyl Acetylacetonate (UAA)," <i>Radiation Protection Dosimetry</i> , 53(1-4):263-267 (1994)
	** A157	FISHMAN <i>et al.</i> , "Characterization of Pectin, Flash-Extracted from Orange Albedo by Microwave Heating, Under Pressure," <i>Carbohydrate Research</i> , 323:126-138 (2000)
	** A158	GARNIER <i>et al.</i> , "Selectivity and Cooperativity in the Binding of Calcium Ions by Pectins," <i>Carbohydrate Research</i> , 256:71-81 (1994)
	** A159	GARNIER <i>et al.</i> , "Phase Diagrams of Pectin - Calcium Systems: Influence of pH, Ionic Strength, and Temperature on the Gelation of Pectins with Different Degrees of Methylation," <i>Carbohydrate Research</i> , 240:219-232 (1993)
	** A160	GEMEINER <i>et al.</i> , "Calcium Pectate Gel could be a Better Alternative to Calcium Alginate Gel in Multiple Applications of Immobilized Cells," <i>Progress in Biotechnology</i> , 2:76-83 (1996)
	** A161	GURNY <i>et al.</i> , "Ocular Therapy with Nanoparticulate Systems for Controlled Drug Delivery," <i>Journal of Controlled Release</i> , 2:353-361 (1985)
	A162	ILLUM, "Nasal Drug Delivery: New Developments and Strategies," <i>Drug Discovery Today</i> , 7(23):1184-1189 (2002)
	** A163	IRESON <i>et al.</i> , "Comparison of nasal pH values in Black and White Individuals with Normal and High Blood Pressure," <i>Clinical Science</i> , 100:327-333 (2001)
	A164	ISHIKAWA <i>et al.</i> , "Insoluble Powder Formulation as an Effective Nasal Drug Delivery System," <i>Pharmaceutical Research</i> , 19(8):1097-1104 (2002)
	** A165	JARVIS <i>et al.</i> , "Structure and Properties of Pectin Gels in Plant Cell Walls," <i>Plant, Cell and Environment</i> , 7:153-164 (1984)
	** A166	JEONG <i>et al.</i> , "Biodegradable Block Copolymers as Injectable Drug-Delivery Systems," <i>Nature</i> , 388:860-862 (1997)
	** A167	JEONG <i>et al.</i> , "Drug Release from Biodegradable Injectable Thermosensitive Hydrogel of PEG-PLGA-PEG Triblock Copolymers," <i>Journal of Controlled Release</i> , 63:155-163 (2000)

**Documents indicated with ** have been previously submitted in a parent application.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Substitute for Form 1449/PTO <h2 style="text-align: center; margin: 0;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center; margin: 0;">(Use as many sheets as necessary)</p>				Complete if Known Application Number 10/652,622 Filing Date August 29, 2003 First Name Inventor NI <i>et al.</i> Art Unit 1635 Examiner Name Unassigned Attorney Docket Number 04137.0003U3	
Sheet	7	of	9		

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.
	A168	JONES <i>et al.</i> , "A Nasal Proteosome™ Influenza Vaccine Containing Baculovirus-Derived Hemagglutinin Induces Protective Mucosal and Systemic Immunity," <i>Vaccine</i> , 21:3706-3712 (2003)
	** A169	KAJIWARA <i>et al.</i> , "Gels Handbook," <i>Academic Press</i> , Volume 1, Chapter 1, Sections 1-2, pp. 3-25 (2001, 1997)
	** A170	LANGER, "Drug Delivery and Targeting," <i>Nature</i> , 392(Supp.):5-10 (1998)
	A171	LICALSI <i>et al.</i> , "A Power Formulation of Measles Vaccine for Aerosol Delivery," <i>Vaccine</i> , 19:2629-2636 (2001)
	** A172	LIN <i>et al.</i> , "Carbopol/Pluronic Phase Change Solutions for Ophthalmic Drug Delivery," <i>Journal of Controlled Release</i> , 69:379-388 (2000)
	** A173	LORIN <i>et al.</i> , "Quantitative Composition of Nasal Secretions in Normal Subjects," <i>Journal of Laboratory and Clinical Medicine</i> , 80(2):275-281 (1972)
	A174	MALCOLMSON <i>et al.</i> , "Dry Powder Formulations for Pulmonary Delivery," <i>PSTT</i> , 1(9):394-398 (1998)
	** A175	MANDAL <i>et al.</i> , "Structure of the D-Galactan Isolated From Aloe barbadensis Miller*," <i>Carbohydrate Research</i> , 86:247-257 (1980)
	** A176	MANDAL <i>et al.</i> , "Characterisation of Polysaccharides of Aloe Barbadensis Miller: Part III – Structure of an Acidic Oligosaccharide," <i>Indian Journal of Chemistry</i> , 22(b):890-893 (1983)
	** A177	MANESS <i>et al.</i> , "Determination of the Degree of Methyl Esterification of Pectins in Small Samples by Selective Reduction of Esterified Galacturonic Acid to Galactose," <i>Analytical Biochemistry</i> , 183:346-352 (1990)
	** A178	MITTERHAUSZEROVÁ <i>et al.</i> , "Interaction of Aminopyrine, 4-Aminoantipyrine, Nicotine Amide, and P-Aminosalicylate with Pectic Acid," <i>Pharmacology</i> , L11:501-507 (1983)
	** A179	MIYAZAKI <i>et al.</i> , "Oral Mucosal Bioadhesive Tablets of Pectin and HPMC: In Vitro and In Vivo Evaluation," <i>Int'l Journal of Pharmaceutics</i> , 204:127-132 (2000)
	** A180	MOE <i>et al.</i> , "Alginates," <i>Food Polysaccharides and Their Applications</i> , 9:245-286 (1995)
	** A181	MUNJERI <i>et al.</i> , "Hydrogel Beads Based on Amidated Pectins for Colon-Specific Drug Delivery: The Role of Chitosan in Modifying Drug Release," <i>Journal of Controlled Release</i> , 46:273-278 (1997)
	A182	NOLAN <i>et al.</i> , "Safety and Immunogenicity of a Live-Attenuated Influenza Vaccine Blended and Filled at Two Manufacturing Facilities," <i>Vaccine</i> , 21:1224-1231 (2003)
	** A183	NURMUKHAMBETOVA <i>et al.</i> , "Interaction of Cephedrin with Polyelectrolytes," <i>News of the Nat'l Academy of Sciences of Republic of Kazakhstan, Chemical Series</i> , 3:58-61 (1995) (English translation provided)
	** A184	PICULELL, "Gelling Carrageenans," <i>Food Polysaccharides and Their Applications</i> , 8:205-239 (1995)
	** A185	PILNIK <i>et al.</i> , "Gelling Agents (Pectins) From Plants For The Food Industry" <i>Advances in Plant Cell Biochemistry and Biotechnology</i> , 1:219-270 (1992)
	A186	PLANTE <i>et al.</i> , "Nasal Immunization with Subunit Proteosome Influenza Vaccines Induces Serum HAI, Mucosal IgA and Protection Against Influenza Challenge," <i>Vaccine</i> , 20:218-225 (2002)
	** A187	PUTNEY <i>et al.</i> , "Improving Protein Therapeutics with Sustained-Release Formulations," <i>Nature Biotechnology</i> , 16:153-157 (1998)
	** A188	RENARD <i>et al.</i> , "Pectins in Mild Alkaline Conditions: β -elimination and Kinetics of Dementylation," <i>Progress in Biotechnology, Pectins and Pectinases</i> , 14:603-608 (1996)

**Documents indicated with ** have been previously submitted in a parent application.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Substitute for Form 1449/PTO <h2 style="text-align: center; margin: 0;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center; margin: 0;">(Use as many sheets as necessary)</p>				Complete if Known Application Number 10/652,622 Filing Date August 29, 2003 First Name Inventor NI <i>et al.</i> Art Unit 1635 Examiner Name Unassigned Attorney Docket Number 04137.0003U3	
Sheet	8	of	9		

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.
	A189	RICHARDSON <i>et al.</i> , "Novel Vaginal Delivery Systems for Calcitonin: I. Evaluation of HYAFF/Calcitonin Microspheres in Rats," <i>Int'l Journal of Pharmaceutics</i> , 115:9-15 (1995)
	** A190	ROLIN, "Pectin," in <i>Industrial Gums</i> , Academic Press, New York, Chapter 10, pg 258-293 (1993)
	** A191	ROMANO <i>et al.</i> , "Latest Developments in Gene Transfer Technology: Achievements, Perspectives, and Controversies over Therapeutic Applications," <i>Stem Cells</i> , 18:19-39 (2000)
	** A192	ROZIER <i>et al.</i> , "Gelrite®: A Novel, Ion-Activated, In-Situ Gelling Polymer for Ophthalmic Vehicles. Effect on Bioavailability of Timolol," <i>Int'l Journal of Pharmaceutics</i> , 57:163-168 (1989)
	** A193	RYDEN <i>et al.</i> , "Effect of Polymers and Microspheres on the Nasal Absorption of Insulin in Rats," <i>Int'l J. Pharm.</i> , 83:1-10 (1992)
	A194	SACCHETTI <i>et al.</i> , "Caffeine Microparticles for Nasal Administration Obtained by Spray Drying," <i>Int'l Journal of Pharmaceutics</i> , 242:335-339 (2002)
	** A195	SCHIPPER <i>et al.</i> , "Nasal Insulin Delivery with Dimethyl-β-Cyclodextrin as an Absorption Enhancer in Rabbits: Powder More Effective than Liquid Formulations," <i>Pharm. Res.</i> , 10(5):682-686 (1993)
	** A196	SCHOLS <i>et al.</i> , "Complex Pectins: Structure Elucidation Using Enzymes," <i>In Process in Biotechnology 14. Pectins and Pectinases</i> , J. Visser and A.G.J. Voragen (Eds.), 3-20 (1996)
	** A197	SHIPUNOVA <i>et al.</i> , "Immobilization of Isoniazid on Pectin Compounds," <i>Institute of Chemical Sciences of Nat'l Academy of Sciences of Republic of Kazakhstan, Alma-ata</i> , 2:83-88 (1990) (English translation provided)
	A198	SINGH <i>et al.</i> , "A Novel Bioadhesive Intranasal Delivery System for Inactivated Influenza Vaccines," <i>Journal of Controlled Release</i> , 70:267-276 (2001)
	** A199	SOMIA <i>et al.</i> , "Gene Therapy: Trials and Tribulations," <i>Nature Reviews</i> , 1:91-99 (2000)
	** A200	SRIAMORNSAK <i>et al.</i> , "Calcium Pectinate Gel Beads for Controlled Release Drug Delivery: I. Preparation and In Vitro Release Studies," <i>Int'l Journal of Pharmaceutics</i> , 160:207-212 (1998)
	** A201	SRIAMORNSAK <i>et al.</i> , "Calcium pectinate gel beads for controlled release drug delivery: II. Effect of formulation and processing variables on drug release," <i>J. Microencapsulation</i> , 16(3):303-313 (1999)
	** A202	SRIAMORNSAK, "Preliminary Investigation of Some Polysaccharides as a Carrier for Cell Entrapment," <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 46:233-236 (1998)
	** A203	SRIAMORNSAK <i>et al.</i> , "Development of sustained release theophylline pellets coated with calcium pectinate," <i>J. of Controlled Release</i> , 47:221-232 (1997)
	** A204	STJERNSCHANTZ <i>et al.</i> , "Anatomy and Physiology of the Eye, Physiological Aspects of Ocular Drug Therapy," <i>Biopharmaceutical Aspects of Ocular Drug Delivery</i> , 1:1-15 (1993)
	** A205	THAKUR <i>et al.</i> , "Chemistry and Uses of Pectin – A Review," <i>Critical Reviews in Food Science and Nutrition</i> , 37(1):47-73 (1997)
	** A206	TIBBITS <i>et al.</i> , "Calcium Binding and Swelling Behaviour of a High Methoxyl Pectin Gel," <i>Carbohydrate Research</i> , 310:101-107 (1998)
	** A207	VADNERE <i>et al.</i> , "Thermodynamic Studies on the Gel-sol Transition of some Pluronic Polyols," <i>International Journal of Pharmaceutics</i> , 22:207-218 (1984)
	** A208	VERMA <i>et al.</i> , "Gene Therapy – Promises, Problems and Prospects," <i>Nature</i> , 389:239-242 (1997)
	** A209	VORAGEN <i>et al.</i> , "Pectins," <i>Food Polysaccharides and Their Applications</i> , 10:287-339 (1995)

**Documents indicated with ** have been previously submitted in a parent application.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Substitute for Form 1449/PTO			Complete if Known	
<h1 style="text-align: center;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h1> <p style="text-align: center;">(Use as many sheets as necessary)</p>			Application Number	10/652,622
			Filing Date	August 29, 2003
			First Name Inventor	NI <i>et al.</i>
			Art Unit	1635
			Examiner Name	Unassigned
			Attorney Docket Number	04137.0003U3
Sheet	9	of	9	

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.
	** A210	VORAGEN <i>et al.</i> , "Determination of the Degree of Methylation and Acetylation of Pectings by H.P.L.C.," <i>Food Hydrocolloids</i> , 1:65-70 (1986)
	** A211	WAKERLY <i>et al.</i> , "Studies on Amidated Pectins as Potential Carriers in Colonic Drug Delivery," <i>J. Pharm. Pharmacol.</i> , 49:622-625 (1997)
	** A212	WAKERLY <i>et al.</i> , "Studies on Drug Release from Pectin/Ethycellulose Film-Coated Tablets: A potential Colonic Delivery System," <i>International Journal of Pharmaceutics</i> , 153:219-224 (1997)
	** A213	YAMADA, "Contribution of Pectins on Health Care," <i>Progress in Biotechnology, Pectins and Pectinases</i> , 14:173-190 (1996)
	** A214	ZHENG <i>et al.</i> , "Salt Effects on the Corr-linking Mechanism of Cupric-Induced Sol-Gel Transition in Alginate Solutions," <i>Carbohydrate Polymers</i> , 35:215:221 (1998)
	** A215	ZHUBANOV <i>et al.</i> , "Immobilization of Promedol on Poly-Sugar Supports," <i>A.B.Bakturov Institute of Chemical Sciences of Nat'l Academy of Sciences of Republic of Kazakhstan, Alma-ata</i> , (5), 27-31(English translation provided)
	** A216	ZHUBANOV <i>et al.</i> , "Pectic Acid and Carboxy Methyl Cellulose as Polymer Hosts for Analgesic Promedol," <i>A.B.Bakturov Institute of Chemical Sciences of Nat'l Academy of Sciences of Republic of Kazakhstan, Alma-ata</i> , 6:55-58(English translation provided)
	** A217	ZHUBANOV <i>et al.</i> , "Application of Carboxy Methyl Cellulose and Pectic Acid to Prolong Clophelin Action," <i>A.B.Bakturov Institute of Chemical Sciences of Nat'l Academy of Sciences of Republic of Kazakhstan, Alma-ata</i> , 1:61-65 (1993) (English translation provided)
EXAMINER:		DATE CONSIDERED:
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

**Documents indicated with ** have been previously submitted in a parent application.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.



BEST AVAILABLE COPY

RECEIVED IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

MAIL STOP PATENT APPLICATION

Commissioner for Patents

P. O. Box 1450

Alexandria, VA 22313-1450

RECEIVED

SEP 09 2003

SIR: PLEASE ACKNOWLEDGE RECEIPT OF THE FOLLOWING:

- ☒ Utility Patent Application Transmittal (2 pages)
☒ U.S. Utility Patent Application, 103 total pages, including:
 ☒ Cover Sheet (1 page) ☒ Abstract (1 page)
 ☒ Specification (76 pages) ☒ Drawings (11 pages)
 ☒ Claims (14 pages; 112 claims)
☒ Authorization to Treat Reply Requiring Extension of Time (2 pages)
☒ Certificate of Express Mailing No. EL992019708US dated August 29, 2003

NEEDLE & ROSENBERG

03940 U.S. PTO

10/652622



08/29/03

In RE to Application of: NI *et al.*

Title "DELIVERY OF PHYSIOLOGICAL AGENTS WITH IN-SITU GELS COMPRISING ANIONIC POLYSACCHARIDES"

Serial No. Unassigned

Filed: August 29, 2003

184680

Reference No.: 04137.0003U3

Confirmation No.: Unassigned
(MAM/rcs)

